Melanocortin Receptor Mechanism Map

The melanocortin family of G-protein-coupled receptors underlies several high-claim peptide categories — tanning, libido, body composition. It is also one of the better-documented unapproved-peptide targets in terms of safety signal, with melanoma case reports, blood-pressure effects, and persistent off-target consequences in published literature.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

Pathway background

The five melanocortin receptors (MC1R through MC5R) are all seven-transmembrane G-protein-coupled receptors that signal primarily through Gαs and cyclic AMP. Their endogenous ligands are derived from proopiomelanocortin (POMC), which is cleaved into adrenocorticotropic hormone (ACTH) and α-, β-, γ-melanocyte-stimulating hormone (α-MSH and family). Different ligands have different selectivity profiles across the five receptors, and the receptors are expressed in tissue-specific patterns that explain the very different physiological effects.

The melanocortin system is one of the more pharmacologically successful unapproved-peptide targets — afamelanotide (an MC1R-selective agonist) is licensed for erythropoietic protoporphyria, and bremelanotide (a non-selective MC3R/MC4R agonist) is licensed in the US for hypoactive sexual desire disorder. Most of the grey-market use of this class, however, is off-label and outside any regulatory framework.

The receptor family at a glance

MC1R — melanocyte pigmentation; α-MSH agonism drives eumelanin production.
MC2R — adrenocortical ACTH receptor; cortisol secretion. Not a target of the peptides on this site.
MC3R — energy homeostasis; appetite regulation.
MC4R — appetite, energy expenditure, sexual function. Disease-associated mutations cause monogenic obesity.
MC5R — exocrine gland regulation. Less pharmacologically studied.

Peptide interactions

Melanotan I (afamelanotide) — selective MC1R agonist licensed in EU/UK for erythropoietic protoporphyria (Scenesse). Approved and prescribed under specialist supervision.
Melanotan II — non-selective melanocortin agonist (binds MC1R, MC3R, MC4R, MC5R); unapproved anywhere; substantial off-label grey-market use with documented adverse events.
PT-141 (bremelanotide) — MC3R/MC4R agonist; approved in US (Vyleesi) for HSDD in pre-menopausal women; not authorised in the UK.

Safety signals — why this map matters

Melanocortin agonists illustrate that a partial clinical evidence base for one indication does not justify off-label or grey-market use for other indications. Pigmentation outcomes are not benign secondary effects; they carry their own oncological literature.

Melanotan II has been linked in case reports and case series to atypical melanocytic lesions, melanoma, eruptive melanocytic naevi, and persistent darkening of existing moles. The mechanism is plausible — MC1R agonism on existing dysplastic melanocytes is hypothesised to accelerate transformation. Cardiac and renal adverse events have also been reported.
PT-141 / bremelanotide causes documented blood pressure increases (transient hypertension is a labelled warning), nausea, flushing, and focal hyperpigmentation with repeated use. Contraindicated in uncontrolled hypertension and cardiovascular disease.
Non-selective melanocortin agonism produces broad off-target effects — by design or by accident — across all five receptors. Selective agonists were developed specifically to avoid this profile.

Regulatory sensitivity

Afamelanotide and bremelanotide are prescription-only medicines where approved. Melanotan II is an unapproved compound widely traded online; the MHRA has issued public-facing warnings about the safety of unauthorised tanning injections. See: POM advertising rules and our adverse events & safety signals page.